Drug Profile


Alternative Names: PF-03446962; PF-3-446-962

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Duke University Medical Center; Fondazione IRCCS Istituto Nazionale dei Tumori; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ACVRL1-protein-antagonists; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Hepatocellular carcinoma; Solid tumours; Urogenital cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Nov 2014 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Metastatic disease) in USA (IV)
  • 06 Nov 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA, Italy & South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top